Genomic Characteristics and Clonal Evolution of EGFR-mutated Lung Adenocarcinoma-Transformed Squamous Carcinoma after EGFR-TKIs Treatment

被引：0
|
作者：
Kang, J. [1 ]
Yang, X. -N. [1 ]
Yan, L. -X. [2 ]
Yan, L. [3 ]
Yang, J. -J. [1 ]
机构：
[1] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Shanghai Tongshu Biotech Co Ltd, Shang Hai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
epidermal growth factor receptor; lung adenocarcinoma to; squamous cell carcinoma tra; drug resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-10
引用
收藏
页码：S335 / S335
页数：1
相关论文
共 12 条
  • [1] Risk Factors of Brain Metastasis during the Course of EGFR-TKIs Therapy for Patients with EGFR-Mutated Advanced Lung Adenocarcinoma
    Zhu, Hui
    Ma, Xiaoyan
    Yu, Jinming
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1484 - S1484
  • [2] Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
    Ma, Xiaoyan
    Zhu, Hui
    Guo, Hongbo
    Han, Anqin
    Wang, Haiyong
    Jing, Wang
    Zhang, Yan
    Kong, Li
    Yu, Jinming
    ONCOTARGET, 2016, 7 (49) : 81906 - 81917
  • [3] Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma
    Yi, Guangming
    Cai, Fanghao
    Liu, Liangzhong
    Liao, Rongxin
    Jiang, Xuan
    Yang, Zhenzhou
    Zhang, Xiaoyue
    FUTURE ONCOLOGY, 2024, 20 (40) : 3477 - 3490
  • [4] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
    Huang, Lei
    Huang, Hao
    Zhou, Xiao-Ping
    Liu, Jin-Feng
    Li, Chun-Rong
    Fang, Min
    Wu, Jun-Rong
    MEDICINE, 2019, 98 (43)
  • [5] Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations
    Wang, Zhijie
    Shen, Zhirong
    Li, Zhenxiang
    Duan, Jianchun
    Fu, Shuai
    Liu, Zhentao
    Bai, Hua
    Zhang, Zemin
    Zhao, Jun
    Wang, Xiaodong
    Wang, Jie
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (32) : 9990 - 9995
  • [6] Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer
    Kubo, Naoki
    Harada, Taishi
    Shiraishi, Yoshimasa
    Nosaki, Kaname
    Nakagaki, Noriaki
    Takeshita, Masafumi
    Ouchi, Hiroshi
    Iwama, Eiji
    Tanaka, Kentaro
    Okamoto, Isamu
    Sasaki, Hiroyuki
    Nakanishi, Yoichi
    ANTICANCER RESEARCH, 2019, 39 (02) : 671 - 677
  • [7] Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
    Yi, Xiao-Fang
    Song, Jun
    Gao, Ruo-Lin
    Sun, Li
    Wu, Zhi-Xuan
    Zhang, Shu-Ling
    Huang, Le-Tian
    Ma, Jie-Tao
    Han, Cheng-Bo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Successful treatment of a patient with an EGFR-mutated pulmonary adenocarcinoma and a history of uremia with erlotinib after gefitinib-induced kidney dysfunction: a case report
    Zhou, L.
    Chen, Z.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2021, 19 (03): : 749 - 753
  • [9] Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment
    Hwang, Soohyun
    Hong, Tae Hee
    Park, Sehhoon
    Jung, Hyun-Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Choi, Yoon-La
    Lee, Se-Hoon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (11) : 4209 - +
  • [10] PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients
    Endoh, Hideki
    Yatabe, Yasushi
    Kosaka, Takayuki
    Kuwano, Hiroyuki
    Mitsudomi, Tetsuya
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (07) : 629 - 634
12